# LAI Intelligence Weekly – December 8, 2025

This week's intelligence highlights Pfizer's competitive positioning in hemophilia with new Hympavzi data at ASH, while regulatory developments include Agios awaiting an overdue FDA decision. Commercial activity intensified as AbbVie led November pharma TV spending with Skyrizi, and safety concerns emerged around Takeda's Adzynma.

## TL;DR

- Pfizer presents phase 3 Hympavzi data at ASH to compete in crowded hemophilia market
- FDA investigating safety signal for Takeda's Adzynma; Otsuka secures first-in-class IgA nephropathy approval
- AbbVie tops November TV ad spending with Skyrizi, narrowly beating J&J's Tremfya

---

## Top Signals – LAI Ecosystem

Key developments spanning clinical data releases, regulatory milestones, commercial strategy, and safety monitoring across major pharma players.

**ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data**  
Pfizer presented new phase 3 data for hemophilia drug Hympavzi at the ASH conference, positioning the asset to compete against established rival treatments. The data release represents Pfizer's effort to gain market share in the competitive hemophilia therapeutic landscape.  
[Read more](https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data)

**Regulatory tracker: Agios awaits FDA decision as target date passes**  
Fierce Pharma is tracking regulatory progress for in-market products including geographic expansions and new indications. Agios is currently awaiting an FDA decision that has exceeded its target action date.  
[Read more](https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025)

**AbbVie revs up Skyrizi spending to top TV ad totals in November, edging out J&J's Tremfya**  
AbbVie led pharmaceutical TV advertising spending in November with Skyrizi, narrowly surpassing Johnson & Johnson's Tremfya. The increased spending follows a record-setting October for pharma TV advertising.  
[Read more](https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya)

**Fierce Pharma Asia—FDA safety probe of Takeda drug; Otsuka kidney disease nod; ADC patent fight**  
The FDA is investigating a safety signal related to Takeda's rare disease medication Adzynma. Separately, Otsuka received first-in-class FDA approval for an IgA nephropathy treatment, while ADC patent litigation continues in the region.  
[Read more](https://www.fiercepharma.com/pharma/fda-safety-probe-takeda-drug-otsuka-kidney-disease-nod-adc-patent-fight)

**Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance**  
Pfizer, GSK, and Shionogi are sponsoring a London musical production focused on raising awareness about antimicrobial resistance. The collaboration represents a novel approach to public health education by major pharmaceutical companies.  
[Read more](https://www.fiercepharma.com/marketing/pfizer-gsk-shionogi-sponsor-london-run-musical-about-antimicrobial-resistance)

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
